A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

NO_LONGER_AVAILABLE

Conditions studied: Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous

In brief

The purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies SGN35-005 and C25001

Key facts

Study ID

NCT01196208

Run by

Seagen Inc.

Last updated by the study team

2020-09-21

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participated in either the SGN35-005 or C25001 clinical study and experienced progression. Patients who received brentuximab vedotin in C25001 must have had an objective response at the time of discontinuation.
• Completed any previous treatment with radiation, chemotherapy, biologics and/or investigational agents at least 4 weeks prior to the first dose of brentuximab vedotin

You may not qualify if…

• History of another primary malignancy that has not been in remission for at least 3 years
• Known cerebral/meningeal disease
• Peripheral neuropathy of grade 2 or greater
• Females who are pregnant or breastfeeding

Where it is running

• Stanford Cancer Center — Stanford, California, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• MD Anderson Cancer Center / University of Texas — Houston, Texas, United States
• Peter MacCallum Cancer Center — Melbourne, Australia
• Leuven University Hospital — Leuven, Belgium
• Specializirana bolnica aktivno lechenie detsa ohcohematologichni zabolyavania Hematologichno — Sofia, Bulgaria
• Specializirana bolnica za aktivno lechenie na hematologichni zabolyavania — Sofia, Bulgaria
• Hopital Saint-Louis/Service d'Hematologie — Paris, Cedex 10, France
• South Lyon Hospital Center, Department of Dermatology — Lyon, France
• Centre Henri Becquerel / Centre Regional de Lutte Contre le Cancer — Rouen, France
• Johannes Wesling Hospital Minden, Department of Dermatology — Minden, Germany
• Szent Istvan es Szent Laszlo Korhaz Rendelointezet Haematologiai es Ossejt-transzplantacios osztaly — Budapest, Hungary
• Debreceni Egyetem Orvos és Egeszsegtudomanyi Centrum, III. sz. Belgyogyaszati Klinika — Debrecen, Hungary
• Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikat Kozpont — Szeged, Hungary
• Polyclinic S. Orsola-Malpighi, Institute of Hematology and Medical Oncology "Lorenzo and Ariosto Seragnoli" — Bologna, Italy
• IRCCS University Hospital San Martino — Genoa, Italy
• Klinika Hematologii, Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi — Lodz, Poland
• Klinika Hematologii, Instytut Hematologii i Transfuzjologii — Warsaw, Poland
• Centrum Onkologii Institut im. Marii Sklodowskiej-Curie — Warsaw, Poland
• Spitalul Clinic Judetean de Urgenta Targu Mures, Sectia Clinica Hematologie si Transplant Medular — Târgu Mureş, Mureș County, Romania
• Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation — Bucharest, Romania
• Institutul Clinic Fundeni, Centrul de Hematologie si Transplant Medular Stefan Berceanu — Bucharest, Romania
• Rossijskij onkologicheskij nauchnyj centr im. N.N. Blokhina RAMN — Moscow, Russia
• Gematologicheskj nauchnyj centr RAMN — Moscow, Russia
• Research Institute of Clinical Immunology — Novosibirsk, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.